As of November 6, 2026, Kymera Therapeutics, Inc. is a publicly traded company (Nasdaq: KYMR). The largest holder reporting an active stake on Schedule 13D is Biotechnology Value Fund LP, at 6.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (14.3%), T. Rowe Price (10.7%), T. Rowe Price (6.7%) (Schedule 13D/A, June 26, 2026).
Is this your company?
About to sign with, pay or invest in Kymera Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kymera Therapeutics, Inc. a real, registered company?
- Kymera Therapeutics, Inc. files with the SEC under CIK 1815442 (its SEC filings).
- Its shares are listed under the ticker KYMR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Watertown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kymera Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Jared Gollob (Form 8-K filed 2026-07-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Kymera Therapeutics, Inc.'s owners and officers?
Kymera Therapeutics, Inc.: incorporated in Delaware; business address in Watertown, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 6.6% |
| Schedule 13G/A, 2026-09-08 | T. Rowe Price Associates, Inc. | 10.7% |
| Schedule 13G/A, 2026-08-14 | T. Rowe Price Associates, Inc. | 8.6% |
| Schedule 13G/A, 2026-08-13 | Atlas Venture Fund X, L.P. | 2.9% |
| Schedule 13D/A, 2026-06-26 | Biotechnology Value Fund L P | 6.3% |
| Schedule 13G, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 6.7% |
| Schedule 13G/A, 2026-05-15 | Wellington Management Group LLP | 4.8% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 14.3% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 5.5% |
| Schedule 13G/A, 2026-01-08 | Fmr LLC | 11.2% |
| Schedule 13D/A, 2025-12-15 | Biotechnology Value Fund L P | 8.5% |
Questions about who owns Kymera Therapeutics, Inc.
Who owns Kymera Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kymera Therapeutics, Inc.: Fmr LLC (14.3%, Schedule 13G/A, filed 2026-05-06), T. Rowe Price Associates, Inc. (10.7%, Schedule 13G/A, filed 2026-09-08), T. Rowe Price Investment Management, Inc. (6.7%, Schedule 13G, filed 2026-05-15), Blackrock, Inc. (6.6%, Schedule 13G/A, filed 2026-10-27) and Biotechnology Value Fund L P (6.3%, Schedule 13D/A, filed 2026-06-26).
Who are the largest shareholders of Kymera Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kymera Therapeutics, Inc. on this page are Fmr LLC (14.3%), T. Rowe Price Associates, Inc. (10.7%) and T. Rowe Price Investment Management, Inc. (6.7%).
When did Fmr LLC buy into Kymera Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-01-08, reporting 11.2%; its latest, Schedule 13G/A filed 2026-05-06, reports 14.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kymera Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kymera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kymera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-27 | Jared Gollob | departed |
Which insiders own Kymera Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Baker Bros. Advisors LP, a director and 10% owner: 7,955,916 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-11).
- , a director and 10% owner: 7,955,916 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-11).
- 667, L.P., a director and 10% owner: 7,955,916 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-11).
- Baker Bros. Advisors (GP) LLC, a director and 10% owner: 7,955,916 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-11).
- Baker Brothers Life Sciences LP, a director and 10% owner: 7,955,916 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-11).
Shares outstanding: 85,371,397 as of 2026-10-23, from the company's latest SEC cover page.
How much has Kymera Therapeutics, Inc. raised?
No fundraising or offering filing from Kymera Therapeutics, Inc. is on file with us.
Keep reading
More on Kymera Therapeutics, Inc. and the records around it.
Kymera Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jul 2026
Companies that share a holder
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026), GENERATION BIO CO. (May 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kymera-therapeutics